Volume 13, Number 7—July 2007
Research
Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1
Somsak Akksilp*, Opart Karnkawinpong*, Wanpen Wattanaamornkiat*, Daranee Viriyakitja†, Patama Monkongdee‡, Walya Sitti*, Dhanida Rienthong†, Taweesap Siraprapasiri†‡, Charles D. Wells§, Jordan W. Tappero‡§, and Jay K. Varma†§
Table 4
Multivariate analysis of risk factors for death among HIV-infected TB patients with outcomes of cured, completed, failed, or died and adjusted for site of treating facility,* Ubon-ratchathani, February 2003 through January 2004†
| Characteristic | Adjusted OR (95% CI) |
|---|---|
| Antiretroviral therapy before or during TB treatment | 0.2 (0.1–0.5) |
| Co-trimoxazole during TB treatment | 1.1 (0.6–2.3) |
| CD4 count (cells/mm3) | |
| >200 | Referent |
| 100–199 | 5.5 (0.6–52.6) |
| 50–99 | 9.3 (1.0–82.9) |
| <50 | 9.7 (1.2–78.4) |
| Unknown | 29.9 (3.8–238.0) |
| Type, location of TB | |
| Sputum smear–positive, pulmonary | Referent |
| Sputum smear–negative, pulmonary | 1.3 (0.7–2.6) |
| Extrapulmonary | 0.5 (0.2–1.0) |
*Data not shown.
†TB, tuberculosis; OR, odds ratio; CI, confidence interval.
Data from this manuscript have been presented in part at the 36th UNION World Conference on Lung Health, Paris, October 2005, and the 15th Annual International AIDS Conference, Bangkok, July 2004.
Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.